The Effect of Dexmedetomidine on Postoperative Quality of Recovery

Kyungmi Kim

Status and phase: Unknown; Phase 4

Conditions: The Effect of Dexmedetomidine on Postoperative Quality of Recovery

Treatments: Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT03468062

GAIRB2018-071

Details and patient eligibility

About

Dexmedetomidine is a selective a2-agonist and a sedative with anti-inflammatory,analgesic, and antiemetic effects, and its use for procedural sedation during endoscopy or ablation for atrial fibrillation has been increasing. It is also used for sedation in the intensive care unit. Recently, it was reported that dexmedetomidine is often used as an adjuvant for general anesthesia. Sympatholysis of dexmedetomidine can attenuate the increased sympathetic tone after surgery and result in antistress effects. In addition, opioid-sparing and analgesic effects are promoted by the perioperative administration of dexmedetomidine. Although it has been reported that the perioperative administration of dexmedetomidine improves quality of recovery after spinal and ENT surgeries, the outcomes for patients who undergo laparoscopic cholecystectomy remain poorly investigated.

The aims of this study were to evaluate the effects of preoperative dexmedetomidine administration on quality of recovery by using the QoR-40 questionnaire in patients who undergo laparoscopic cholecystectomy.

Enrollment: 90 estimated patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patients who undergo elective cholecystectomy
• Adults (20~75 years old)
• an American Society of Anesthesiologists physical status of I or II

Exclusion criteria

• The patients do not provide written informed consent
• The patients have had allergic response to dexmedetomidine.
• The patients have mood disorder or anxiety disorder.
• The patients are not able to express their emotions.
• The pregnant women

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

90 participants in 2 patient groups, including a placebo group

Dexmedetomidine

Experimental group

Description:

0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.

Treatment:

Drug: Dexmedetomidine

Placebo

Placebo Comparator group

Description:

Only normal saline 100mL is administered for 5 minutes after anesthetic induction.

Treatment:

Drug: Dexmedetomidine